Tag: HUTCHMED (China) Limited

Tag Visualization: Top 50 related tags by occurrence

Recent Related Articles to HUTCHMED (China) Limited

HUTCHMED announces savolitinib approved in China for patients with lung cancer with MET exon ...

Added to Collection on: 2021-06-22 17:15:00

Tags for this article:

Organic compounds
Chemical compounds
Health sciences
Lung cancer
Breakthrough therapy
Orphan drugs
Quinazolines
AstraZeneca
Medical research
Protein kinase inhibitor
Gefitinib
Durvalumab
Hutchison China MediTech
HUTCHMED (China) Limited
AstraZeneca plc

Click the tags to see associated articles and topics

View Article Details
HUTCHMED Announces First Commercial Sale of ORPATHYS® in China, Triggering a US$25 ...

Added to Collection on: 2021-07-13 06:00:00

Tags for this article:

Lung cancer
Chemical compounds
Organic compounds
Aromatic compounds
Quinazolines
Breakthrough therapy
Non-small-cell lung carcinoma
Tyrosine kinase inhibitors
Protein kinase inhibitor
Tyrosine kinase
Icotinib
Gefitinib
HUTCHMED (China) Limited
China

Click the tags to see associated articles and topics

View Article Details
HUTCHMED Highlights Clinical Data to be Presented at the Upcoming 2021 ESMO Virtual ...

Added to Collection on: 2021-09-07 08:26:15

Tags for this article:

Health sciences
Life Sciences
Health
Pharmaceutical industry
Drug discovery
AstraZeneca
Medical research
Södertälje Municipality
Chemotherapy
Medication
Preclinical development
fruquintinib
China
HUTCHMED (China) Limited

Click the tags to see associated articles and topics

View Article Details
HUTCHMED and AstraZeneca Initiate SANOVO Phase III Trial of ORPATHYS ... - PharmiWeb.com

Added to Collection on: 2021-09-09 13:52:01

Tags for this article:

Clinical medicine
Cancer treatments
Cancer
Lung cancer
Breakthrough therapy
Orphan drugs
Quinazolines
Cancer immunotherapy
Non-small-cell lung carcinoma
Durvalumab
Protein kinase inhibitor
Epidermal growth factor receptor
AstraZeneca plc
China
HUTCHMED (China) Limited

Click the tags to see associated articles and topics

View Article Details
HUTCHMED and AstraZeneca Initiate SAMETA Global Phase III Trial of Savolitinib in ...

Added to Collection on: 2024-02-25 17:15:33

Tags for this article:

Clinical medicine
Kidney cancer
Cancer treatments
Cancer
Lung cancer
Tyrosine kinase receptors
Papillary renal cell carcinoma
PD-1 and PD-L1 inhibitors
Durvalumab
Non-small-cell lung carcinoma
Renal cell carcinoma
C-Met
HUTCHMED (China) Limited
Sutent
AstraZeneca plc
China

Click the tags to see associated articles and topics

View Article Details